← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cynvec, Llc
New York, NY
$4,400,000
Total funding
2
Grants
Funding over time
peak $1.1M · FY2016–22$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,400,000 · 2
By mechanism
R44$4,400,000 · 2
Investigators at Cynvec, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$1,133,263
R44 · FY2021 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$1,004,186
R44 · FY2017 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$995,814
R44 · FY2016 · CA
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$866,737
R44 · FY2022 · CA
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$400,000
R44 · FY2020 · CA